Cited by 60Antifungal resistance and susceptibilityFungal Infections and StudiesCOVID-19 Clinical Research Studies

Increased Deaths From Fungal Infections During the Coronavirus Disease 2019 Pandemic—National Vital Statistics System, United States, January 2020–December 2021

Open access
Gold, Jeremy A W, Ahmad, Farida B, Cisewski, Jodi A, Rossen, Lauren M, Montero, Alejandro J, Benedict, Kaitlin, Jackson, Brendan R, Toda, Mitsuru·2023·Clinical Infectious Diseases

Abstract

Background: Coronavirus disease 2019 (COVID-19)–associated fungal infections cause severe illness, but comprehensive data on disease burden are lacking. We analyzed US National Vital Statistics System (NVSS) data to characterize disease burden, temporal trends, and demographic characteristics of persons dying of fungal infections during the COVID-19 pandemic. Methods: Using NVSS’s January 2018–December 2021 Multiple Cause of Death Database, we examined numbers and age-adjusted rates (per 100 000 population) of deaths due to fungal infection by fungal pathogen, COVID-19 association, demographic characteristics, and year. Results: Numbers and age-adjusted rates of deaths due to fungal infection increased from 2019 (n = 4833; rate, 1.2 [95% confidence interval, 1.2–1.3]) to 2021 (n = 7199; rate, 1.8 [1.8–1.8] per 100 000); of 13 121 such deaths during 2020–2021, 2868 (21.9%) were COVID-19 associated. Compared with non–COVID-19–associated deaths (n = 10 253), COVID-19–associated deaths more frequently involved Candida (n = 776 [27.1%] vs n = 2432 [23.7%], respectively) and Aspergillus (n = 668 [23.3%] vs n = 1486 [14.5%]) and less frequently involved other specific fungal pathogens. Rates of death due to fungal infection were generally highest in nonwhite and non-Asian populations. Death rates from Aspergillus infections were approximately 2 times higher in the Pacific US census division compared with most other divisions. Conclusions: Deaths from fungal infection increased during 2020–2021 compared with previous years, primarily driven by COVID-19–associated deaths, particularly those involving Aspergillus and Candida. Our findings may inform efforts to prevent, identify, and treat severe fungal infections in patients with COVID-19, especially in certain racial/ethnic groups and geographic areas.

Integrity signals

Registry

Crossref · 10.1093/cid/ciac489

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Analyses of 2019-2021 large health care claims and vital statistics data found an increase in the rates of hospitalizations and deaths caused by fungal infections, including invasive candidiasis, potentially related to a COVID-19-related increase in patients with critical illness and limitations in enforcement of infection prevention and control measures.

    “Analyses of 2019–2021 large health care claims and vital statistics data found an increase in the rates of hospitalizations and deaths caused by fungal infections, including invasive candidiasis (18,19), potentially related to a COVID-19–related increase in patients with critical illness and limitations in enforcement of infection prevention and control measures (20).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gold, J. A. W., Ahmad, F. B., Cisewski, J. A., Rossen, L. M., Montero, A. J., Benedict, K., Jackson, B. R., & Toda, M.
Affiliations
  • Centers for Disease Control and Prevention (US)
  • National Center for Health Statistics (US)
Corresponding author
Gold, Jeremy A W
Venue
Clinical Infectious Diseases
Published
2022-08-03
Volume
76
Issue
3
Pages
e255-e262
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W4283121322
Cited by
60
References
3
Citations by year
2026: 3 · 2025: 14 · 2024: 24 · 2023: 14 · 2022: 5
FWCI
6.97
Type
journal article
Language
en
Open access
Locations
  • Clinical Infectious Diseases (publishedVersion, public-domain)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
COVID-19 pandemic, fungal infection, fungal infection mortality, Aspergillus, Candida, disease burden, temporal trends, racial and ethnic disparities, regional variation, United States
MeSH terms
COVID-19, Humans, Mycoses, United States, Vital Statistics, Racial Groups, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review